Bio-Path rises as experimental cancer drugs show promise in ongoing trials

Bio Path Holdings

21/08/2024 12:49

** Shares of Bio-Path Holdings  BPTH.O  rise 12.8% to $1.67
premarket
    ** Drug developer says it saw extended treatment durability
from a combination therapy using its experimental drug
prexigebersen in an ongoing mid-stage trial testing the
combination against a type of blood cancer
    ** Co also says its other cancer drug candidate BP1001-A
showed tumor regression in the first patient administered a
higher dose of the drug in an ongoing early-stage study
    ** Up to last close, stock was down 84% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))